These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 11402305)

  • 21. Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice.
    Sas S; Chan T; Sami A; El-Gayed A; Xiang J
    Cancer Gene Ther; 2008 Oct; 15(10):655-66. PubMed ID: 18421311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene-specific inhibition of breast carcinoma in BALB-neuT mice by active immunization with rat Neu or human ErbB receptors.
    Masuelli L; Focaccetti C; Cereda V; Lista F; Vitolo D; Trono P; Gallo P; Amici A; Monaci P; Mattei M; Modesti M; Forni G; Kraus MH; Muraro R; Modesti A; Bei R
    Int J Oncol; 2007 Feb; 30(2):381-92. PubMed ID: 17203220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antimetastatic activity of a preventive cancer vaccine.
    Nanni P; Nicoletti G; Palladini A; Croci S; Murgo A; Antognoli A; Landuzzi L; Fabbi M; Ferrini S; Musiani P; Iezzi M; De Giovanni C; Lollini PL
    Cancer Res; 2007 Nov; 67(22):11037-44. PubMed ID: 18006850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro and in vivo antisense-mediated growth inhibition of a mammary adenocarcinoma from MMTV-neu transgenic mice.
    Sacco MG; Barbieri O; Piccini D; Noviello E; Zoppé M; Zucchi I; Frattini A; Villa A; Vezzoni P
    Gene Ther; 1998 Mar; 5(3):388-93. PubMed ID: 9614559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins.
    Quaglino E; Mastini C; Amici A; Marchini C; Iezzi M; Lanzardo S; De Giovanni C; Montani M; Lollini PL; Masucci G; Forni G; Cavallo F
    Cancer Res; 2010 Apr; 70(7):2604-12. PubMed ID: 20332241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein.
    Disis ML; Gralow JR; Bernhard H; Hand SL; Rubin WD; Cheever MA
    J Immunol; 1996 May; 156(9):3151-8. PubMed ID: 8617935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MMTV promoter hypomethylation is linked to spontaneous and MNU associated c-neu expression and mammary carcinogenesis in MMTV c-neu transgenic mice.
    Zhou H; Chen WD; Qin X; Lee K; Liu L; Markowitz SD; Gerson SL
    Oncogene; 2001 Sep; 20(42):6009-17. PubMed ID: 11593408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mesenchymal stromal cells expressing ErbB-2/neu elicit protective antibreast tumor immunity in vivo, which is paradoxically suppressed by IFN-gamma and tumor necrosis factor-alpha priming.
    Romieu-Mourez R; François M; Abate A; Boivin MN; Birman E; Bailey D; Bramson JL; Forner K; Young YK; Medin JA; Galipeau J
    Cancer Res; 2010 Oct; 70(20):7742-7. PubMed ID: 20924101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insertion of the DNA for the 163-171 peptide of IL1beta enables a DNA vaccine encoding p185(neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice.
    Rovero S; Boggio K; Di Carlo E; Amici A; Quaglino E; Porcedda P; Musiani P; Forni G
    Gene Ther; 2001 Mar; 8(6):447-52. PubMed ID: 11313823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors.
    Tegerstedt K; Lindencrona JA; Curcio C; Andreasson K; Tullus C; Forni G; Dalianis T; Kiessling R; Ramqvist T
    Cancer Res; 2005 Jul; 65(13):5953-7. PubMed ID: 15994974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system.
    Croci S; Recktenwald CV; Lichtenfels R; Nicoletti G; Dressler SP; De Giovanni C; Astolfi A; Palladini A; Shin-ya K; Landuzzi L; Nanni P; Lollini PL; Seliger B
    Proteomics; 2010 Nov; 10(21):3835-53. PubMed ID: 20957756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice.
    Jabrane-Ferrat N; Campbell MJ; Esserman LJ; Peterlin BM
    Cancer Gene Ther; 2006 Nov; 13(11):1002-10. PubMed ID: 16841083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of different plasmid DNA delivery systems for immunization against HER2/neu in a transgenic murine model of mammary carcinoma.
    Smorlesi A; Papalini F; Amici A; Orlando F; Pierpaoli S; Mancini C; Provinciali M
    Vaccine; 2006 Mar; 24(11):1766-75. PubMed ID: 16288939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Active signaling by Neu in transgenic mice.
    DiGiovanna MP; Lerman MA; Coffey RJ; Muller WJ; Cardiff RD; Stern DF
    Oncogene; 1998 Oct; 17(14):1877-84. PubMed ID: 9778054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of light regimen and melatonin on the development of spontaneous mammary tumors in HER-2/neu transgenic mice is related to a downregulation of HER-2/neu gene expression.
    Baturin DA; Alimova IN; Anisimov VN; Popovich IG; Zabezhinski MA; Provinciali M; Mancini R; Franceschi C
    Neuro Endocrinol Lett; 2001 Dec; 22(6):441-7. PubMed ID: 11781542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine.
    Dakappagari NK; Douglas DB; Triozzi PL; Stevens VC; Kaumaya PT
    Cancer Res; 2000 Jul; 60(14):3782-9. PubMed ID: 10919651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccination strategy determines the emergence and dominance of CD8+ T-cell epitopes in a FVB/N rat HER-2/neu mouse model of breast cancer.
    Singh R; Paterson Y
    Cancer Res; 2006 Aug; 66(15):7748-57. PubMed ID: 16885378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of mammary carcinogenesis by systemic interleukin 12 or p185neu DNA vaccination in Her-2/neu transgenic BALB/c mice.
    Di Carlo E; Rovero S; Boggio K; Quaglino E; Amici A; Smorlesi A; Forni G; Musiani P
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):830s-837s. PubMed ID: 11300480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
    Gritzapis AD; Mahaira LG; Perez SA; Cacoullos NT; Papamichail M; Baxevanis CN
    Cancer Res; 2006 May; 66(10):5452-60. PubMed ID: 16707474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice.
    Jacquemart IC; Springs AE; Chen WY
    Int J Oncol; 2009 Feb; 34(2):517-28. PubMed ID: 19148488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.